Pharmaceutical start-up AcadeMab Biomedical Inc (研生生醫) said it has been developing a COVID-19 antibody drug, an endeavor not being undertaken by many other Taiwanese pharmaceutical firms.
The company was spun off from Academia Sinica’s Institute of Cellular and Organismic Biology in 2020 and has only 16 employees. It has set its sights on the innovative field of the monoclonal antibody treatment of tumors.
The start-up began developing antibody drugs in January, after seeing that COVID-19 vaccines could not effectively protect people from new variants of SARS-CoV-2, AcadeMab Biomedical chief strategy officer Pearl Fong (俸清珠) said in an interview with the Taipei Times on Thursday.
Photo courtesy of AcadeMab Biomedical Inc
The development of COVID-19 antibody drugs focuses on the sequences of the antibodies produced in the body following vaccination, Fong said.
The method does not require any information on the sequences of SARS-CoV-2, she said.
“Specifically, we need to know the DNA sequences of the Y-shaped antibodies carried by people’s memory B cells. Once we obtain the sequences, we can replicate the antibodies,” she added.
The start-up for at least four weeks collected blood samples from five people who had received three doses of COVID-19 vaccines. It then used a method called “cell shorting” to isolate memory B cells and used genetic engineering to decode the sequences of the antibody, AcadeMab Biomedical project manager Chiang Pao-yin (姜伯穎) said.
Getting the right sequences was not easy, Chiang said.
A 20 to 30 milliliter blood sample contains about 40 million cells, from which about 100,000 memory B cells can be isolated, Chiang said.
Using advanced technology, the company initially obtained about 2,000 sequences of antibodies and selected 163 that were expected to be the most effective in fighting against SARS-CoV-2 variants, he said.
“It is like making a key. It must not only have the right shape to fit in the hole, but it also has to be long enough to be used. The right antibodies must not only bind with the spike protein of the virus, but bind firmly,” Chiang said.
The start-up selected 10 sequences and tested them against the Omicron subvariants of SARS-CoV-2 and eventually chose four that showed the most potential, Chiang said, adding that its experimental drug is called SB-001.
Explaining how antibody drugs fight against new SARS-CoV-2 variants while vaccines cannot, Fong said that vaccines and antibody drugs use different mechanisms.
Vaccines prompt the immune system to produce antibodies, but after a given period, only a few antibodies that are most effective against a variant remain in the body, Fong said.
However, it is possible that these antibodies cannot attack new subvariants, she said.
Developers of COVID-19 antibody drugs have deep knowledge of antibody sequences, Fong said.
“It’s like we have a database. We can always research which sequence works best against the latest subvariant and change our formula accordingly,” Fong said.
An antibody that does not work well against an older subvariant could be effective against a new subvariant, she added.
“That has been the case with Eli Lilly and Co. Its first two antibody drugs were approved, but they did not work against later Omicron subvariants. However, the company found another sequence and used it to develop a new antibody drug,” Fong said.
AcadeMab Biomedical is one of only a few Taiwanese companies working on COVID-19 antibody drugs, she said.
Fong said there are two reasons that Taiwanese companies prefer to develop COVID-19 vaccines over antibody drugs, with about 10 firms working on vaccines.
“First, vaccines use fewer proteins than antibody drugs, so vaccine developers can conduct research more easily with limited manufacturing capacity. Second, the requirements for clinical trials involving antibody drugs are much stricter than those for vaccines,” she said.
Antibody drugs are mainly used for treatment instead of prevention, Fong said, adding that they can be used for prevention in some cases, she said.
People who are planning to travel to high-risk areas could take the drugs before embarking on their trip, she said.
As AcadeMab Biomedical focuses on research, it plans to find a manufacturing partner to codevelop SB-001, Fong said, adding that the company has been in talks with several firms and hopes to finalize a deal by the end of this year.
It plans to apply for emergency use authorization in the US and hopes to start phase 1 human trials by June next year, she said.
The US dollar on Friday rose against the euro, but pared gains late in a session that was muddied by quarter-end trading, while riskier commodity-led currencies fell sharply after European inflation hit a record high and US consumer spending increased faster than expected. Although the dollar index was showing its biggest quarterly gain since the first quarter 2015, but was registered its first weekly decline in three weeks. Sterling rose against the dollar after falling earlier in the day. The pound last showed four straight sessions of gains followed by wild declines on concerns about Britain’s plan to slash taxes and pay
SAMSUNG DISTANT SECOND: Top local chip fims served nearly two-thirds of the global market in Q2, while Samsung kept South Korea competitive with its 16.5 percent share Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) remained the world’s largest contract chipmaker in the second quarter of the year with a 53.4 percent share of the global pure-play foundry market, the Taipei-based market information advisory firm TrendForce Corp (集邦科技) said in a research report on Tuesday. Despite TSMC’s market share dipping slightly from 53.6 percent in the first quarter, it was still far ahead of its rivals, TrendForce said. TSMC continued to benefit from emerging technologies, such as high-performance computing devices, the Internet of Things and automotive electronics, as it posted US$18.15 billion in sales in the second quarter, up 3.5 percent
Moderna Inc has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale in the country, the Financial Times reported on Saturday, citing people familiar with the matter. The Cambridge, Massachusetts-based pharmaceutical company turned down China’s request to disclose the formula for its mRNA vaccine because of commercial and safety concerns, the newspaper said, citing people involved in negotiations that took place from 2020 to last year, adding that the vaccine maker is still “eager” to sell the product to China. The company had “given up”
GLOBAL EXPANSION: The Taichung bank is expected to complete the takeover of the Los Angeles-based lender in the spring, in a transaction valued at US$82.1 million Taichung Commercial Bank (TCB, 台中商銀) on Saturday said that its board of directors has approved a plan to acquire California-based American Continental Bank as part of an effort to expand its global reach. Pending regulatory approvals, TCB said it would create a subsidiary to acquire American Continental Bancorp, the holding company of American Continental Bank, through a reverse triangular merger. That would allow the Taiwanese bank to hold a 100 percent stake in American Continental Bancorp, it said. TCB said it plans to acquire the US bank at US$41.48 per share, but the actual cash consideration would be determined at the deal’s close. The
RSS